CHARM Therapeutics appoints Dr Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical Development
30 Abril 2024 - 6:00AM
PRESS RELEASE
CHARM Therapeutics appoints Dr Nicholas
Edmunds as Chief Development Officer, Head of Pre-Clinical
Development
LONDON – 30 April 2024 -- CHARM
Therapeutics (“CHARM”, “The Company”), a protein-ligand
intelligence company turning prediction into impactful medicines,
today announces the appointment of Dr Nicholas Edmunds as Chief
Development Officer, Head of Pre-Clinical Development.
In this role, he will be responsible for
advancing CHARM’s proprietary oncology programs towards the clinic
and building out a broader translational pharmacology and
preclinical development capability.
Dr Edmunds has more than two decades of
experience in preclinical development, translational research, and
drug discovery. He joins CHARM Therapeutics after holding several
senior positions, including his most recent role as Chief
Technology Officer at Mission Therapeutics, a company focused on
developing novel DUB inhibitors for serious diseases including
Parkinson’s Disease and Alzheimer’s Disease. In this position, he
contributed to the development of the company’s proprietary drug
discovery platform.
Prior to joining Mission Therapeutics, Dr
Edmunds worked as the Head of New Modalities, Drug Safety and
Metabolism at AstraZeneca. He also spent 12 years at Pfizer working
within Discovery and Preclinical Development functions in both the
UK and the US. Dr Edmunds also holds a BSc in Pharmacology from the
University of Leeds and a PhD from the University of Bath.
Laksh Aithani, Co-Founder, Chief
Executive Officer and Board Member of CHARM Therapeutics,
said: “On behalf of the entire team, I would like to
warmly welcome Nick. DragonFold, our unique protein-ligand
intelligence platform, optimizes protein-ligand binding
interactions and offers category-leading accuracy in co-folding
prediction. We want to leverage DragonFold to discover innovative
new treatments in oncology; Nick’s expertise in drug discovery and
translational development will be of immense value as we continue
to evolve our platform and further develop our proprietary
pipeline.”
Dr Nicholas Edmunds, Chief Development
Officer, Head of Pre-Clinical Development at CHARM Therapeutics,
said: “CHARM is tackling the hardest challenges in the
optimization of protein-ligand interactions in order to create
powerful new medicines. With a unique blend of deep learning
computing, small molecule chemistry, structural sciences and cancer
biology expertise, CHARM is at the forefront of creating the
game-changing medicines of the future. I am incredibly excited to
be playing a part in this transformation of the biopharma paradigm
and look forward to working with the whole team.”
ENDS
For further information, please
contact:
CHARM Therapeutics
Laksh Aithani, Chief Executive Officer
Phone +44 7933 185425
laksh@charmtx.com
ICR Consilium
Amber Fennell /Jessica Hodgson / Davide
Salvi
Phone: 44 (0)20 3709 5700
charm@consilium-comms.com
About CHARM Therapeutics
CHARM Therapeutics is a protein-ligand
intelligence company turning advanced protein-ligand prediction
into impactful medicines.
CHARM’s advanced protein-ligand prediction platform, DragonFold,
provides unique 3D insights into the dynamic structure of the
protein-ligand binding interactions, with the potential for
profound impacts on the design of novel molecules and delivery of
new medicines.
The Company’s initial focus is novel small
molecules to treat cancer, but the technology is potentially
applicable to many other therapeutic areas.
Cambridge and London-based CHARM has raised $70
million to date and is building an interdisciplinary and
entrepreneurial team, combining leaders from the fields of AI and
biotechnology. It is supported by high quality international
investors including OrbiMed, F-Prime Capital, General Catalyst,
Khosla Ventures, Bristol Myers Squibb, NVIDIA and Grep VC For more
information, please visit: www.charmtx.com